BioAtla BCAB 深 沪
等待开盘 07-22 09:30:00 美东时间
3.69
-0.010
-0.27%
华盛通- 最 高3.855
- 今 开3.70
- 成交量 3.64万股
- 最 低 3.6349
- 昨 收 3.70
- 总市值 612.38万
- 52周最高 71.50
- 市盈率 静 --
- 换手率 2.20%
- 52周最低 3.12
- 委 比 58.73%
- 总股本 165.96万
- 历史最高 3831.50
- 量 比 1.09
- 振 幅 5.95%
- 历史最低 3.6349
- 每 手 1
- 风险率 14.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Context Therapeutics Announces Amendment To Its Exclusive License Agreement With BioAtla To Remove All Future Milestone And Royalty Obligations For CT-202 In Exchange For A $4.5M Upfront Payment And A Final $2M Payment Due By August 1
Phase 1 initiation for CT-202 trial expected in third quarter of 2026
05-18 18:49
Context Therapeutics pays USD 6.5 million for fully paid-up CT-202 license from BioAtla
Context Therapeutics pays USD 6.5 million for fully paid-up CT-202 license from BioAtla Context Therapeutics amended its exclusive CT-202 license with BioAtla to eliminate all future milestone and royalty obligations in exchange for a fully paid-up, non-terminable license. The amendment requires a U
05-18 18:47
Context Therapeutics pays USD 6.5 million to buy out CT-202 milestones, royalties
Context Therapeutics pays USD 6.5 million to buy out CT-202 milestones, royalties Context Therapeutics amended its exclusive license agreement with BioAtla for CT-202, eliminating all future milestone and royalty obligations. The amendment requires a USD 4.5 million upfront payment, with a final USD
05-18 18:47
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Context Therapeutics amended its license agreement with BioAtla, removing future milestones and royalties for CT-202 in exchange for a $4.5 million upfront payment and a $2.0 million payment by August 1, 2026. CT-202, a Nectin-4 x CD3 T cell engager, targets Nectin-4, a protein overexpressed in various solid tumors. Its pH-dependent design aims to minimize adverse effects. Phase 1 trials for CT-202 are expected to begin in Q3 2026.
05-18 10:45
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 307.1% to $6.31 durin...
04-02 01:06
BioAtla Begins Strategic Review Following 2025 Results
BioAtla ( ($BCAB) ) has shared an update. On March 31, 2026, BioAtla reported f...
04-01 07:46
BioAtla Q4 EPS $(0.16) Beats $(0.30) Estimate, Sales $2.000M Beat $700.000K Estimate
BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.30) by 47.19 percent. This is a 46.67 percent increase over losses of $(0.30) per share from the same
04-01 05:03
BioAtla shares are trading lower after the company announced a 50-for-1 share consolidation.
BioAtla shares are trading lower after the company announced a 50-for-1 share c...
04-01 04:20
BioAtla to implement 50-for-1 share consolidation
BioAtla (BCAB) on Tuesday said it will carry out a 50-for-1 share consolidation of its common stock, effective April 6, 2026, as it seeks to raise its share price to meet the $1.00 minimum bid require...
04-01 04:12
BioAtla Announces 50-For-1 Share Consolidation, Effective April 6
BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that
04-01 04:09
